JP2014520767A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520767A5
JP2014520767A5 JP2014517492A JP2014517492A JP2014520767A5 JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5 JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5
Authority
JP
Japan
Prior art keywords
group
atoms
hal
cyc
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517492A
Other languages
English (en)
Japanese (ja)
Other versions
JP6116554B2 (ja
JP2014520767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/002469 external-priority patent/WO2013004332A1/en
Publication of JP2014520767A publication Critical patent/JP2014520767A/ja
Publication of JP2014520767A5 publication Critical patent/JP2014520767A5/ja
Application granted granted Critical
Publication of JP6116554B2 publication Critical patent/JP6116554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517492A 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環 Expired - Fee Related JP6116554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505376P 2011-07-07 2011-07-07
US61/505,376 2011-07-07
PCT/EP2012/002469 WO2013004332A1 (en) 2011-07-07 2012-06-11 Substituted azaheterocycles for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2014520767A JP2014520767A (ja) 2014-08-25
JP2014520767A5 true JP2014520767A5 (enExample) 2015-07-30
JP6116554B2 JP6116554B2 (ja) 2017-04-19

Family

ID=46354143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517492A Expired - Fee Related JP6116554B2 (ja) 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環

Country Status (9)

Country Link
US (1) US9199962B2 (enExample)
EP (1) EP2729459B1 (enExample)
JP (1) JP6116554B2 (enExample)
CN (1) CN103649074B (enExample)
AU (1) AU2012280725B2 (enExample)
CA (1) CA2840883C (enExample)
ES (1) ES2698847T3 (enExample)
IL (1) IL230218A (enExample)
WO (1) WO2013004332A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
RU2015107550A (ru) * 2012-08-23 2016-10-10 Ф. Хоффманн-Ля Рош Аг Новые фенилпиридин/пиразинамиды для лечения рака
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2014138460A1 (en) 2013-03-07 2014-09-12 Northwestern University 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
WO2016073623A2 (en) * 2014-11-04 2016-05-12 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
JP7202315B2 (ja) * 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のbcl6阻害剤
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
WO2020116296A1 (ja) 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
US12448362B2 (en) 2020-05-19 2025-10-21 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound and fluorine-containing pyrimidinone compound
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
EP4431502A4 (en) 2021-11-12 2025-11-05 Unimatec Co Ltd PYRIMIDINE COMPOUNDS CONTAINING FLUORIDE, AGENT FOR CONTROLLING HARMFUL FUNGI AND PROCESS FOR PRODUCING PYRIMIDINE COMPOUNDS CONTAINING FLUORIDE
KR20250004854A (ko) * 2022-04-29 2025-01-08 장슈 야홍 메디텍 코퍼레이션 리미티드 피리미딘 화합물, 이의 제조 방법 및 이의 약학적 용도
CN120202201A (zh) * 2022-11-04 2025-06-24 深圳晶泰科技有限公司 泛素特异性蛋白酶1的抑制剂及其应用
KR20260033560A (ko) * 2023-07-05 2026-03-10 장슈 야홍 메디텍 코퍼레이션 리미티드 피리미딘 화합물, 이의 제조 방법 및 이의 의학적 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0640599T3 (da) 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-Aminopyrimidin-derivater
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
HK1054393B (en) * 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US7731985B2 (en) * 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7459460B2 (en) * 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200519094A (en) * 2003-07-02 2005-06-16 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
MXPA06010900A (es) * 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2008113255A1 (fr) * 2007-03-16 2008-09-25 The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques
MX2009010127A (es) 2007-03-22 2009-11-05 Vertex Pharma Compuestos utiles como inhibidores de janus cinasas.
US20090048282A1 (en) * 2007-08-14 2009-02-19 Wyeth Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027736A2 (en) 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
JP2010540892A (ja) 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー 抗炎症活性を有する化合物をスクリーニングする方法
JP2010126496A (ja) * 2008-11-28 2010-06-10 Mitsubishi Tanabe Pharma Corp 複素環化合物
US8673891B2 (en) * 2009-02-06 2014-03-18 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
WO2010126922A1 (en) 2009-04-30 2010-11-04 Glaxosmithkline Llc Benzimidazolecarboxamides as inhibitors of fak
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods

Similar Documents

Publication Publication Date Title
JP2014520767A5 (enExample)
JP2012506389A5 (enExample)
JP2013501047A5 (enExample)
JP2016503797A5 (enExample)
AR118341A2 (es) Mezclas fungicidas ternarias
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2014508753A5 (enExample)
JP2012092103A5 (enExample)
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
JP2014508811A5 (enExample)
JP2015522650A5 (enExample)
JP2012516871A5 (enExample)
JP2018533593A5 (enExample)
JP2008509166A5 (enExample)
HRP20161103T1 (hr) Kemijski spojevi
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2013537203A5 (enExample)
JP2012508252A5 (enExample)
JP2011219498A5 (enExample)
JP2013532668A5 (enExample)
JP2015500842A5 (enExample)
JP2012532883A5 (enExample)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий